Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Based on data supporting the use of cyclophosphamide and etoposide both as single agents in
combination and a Phase I study showing acceptable toxicity with a chronic dosing regimen, we
propose a Phase II clinical trial. This protocol establishes a model that will test the
hypothesis that the use of etoposide and cyclophosphamide early in the course of prostate
cancer progression, when fewer tumor cells are present, will have greater anti-tumor
activity. We plan to treat patients with stage D0 prostate cancer to assess toxicity and
anti-tumor activity.
Phase:
Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)